

Supplementary

Pri-miR526b and Pri-miR655 Are Potential Blood Biomarkers for Breast Cancer

Mousumi Majumder, Kingsley Chukwunonso Ugwuagbo, Sujit Maiti, Peeyush K Lala and Muriel Brackstone

Table S1. Clinical characteristics of breast cancer subject and control subject demographics of the samples from the Ontario Institute for Cancer Research.

Characteristics		Control <i>n</i> = 20	Breast Cancer <i>n</i> = 20 (100%)
Sex	Male	0	0
	Female	20	20
Age (years)	Mean ± SD (range)	54.39 ± 16.95 (27-87)	67.25 ± 18.17 (32-92)
Tumor Receptor Status	ER+ve (%)		15 (75.00)
	ER-ve (%)		2 (11.11)
	PR+ve (%)		14 (70.00)
	PR-ve (%)		3 (15.00)
	HER2+ve (%)		3 (15.00)
	HER2-ve (%)		12 (60.00)
T-N-M (Tumor) Staging	0		1 (5.00)
	I		1 (5.00)
	II		13 (65.00)
	III		5 (25.00)